Molecular Evaluation of Endometrium After Endometrial Injury
Molecular Evaluation of Endometrium Obtained From Women With Repeated Implantation Failure (RIF) After Endometrial Injury in Compare to Women Without Endometrial Injury; Phase 3 Clinical Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Tehran, Iran, Islamic Republic of
- Royan Institute
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- < 40 years old
- Patients had history of 3 failed consecutive cycles of IVF / ICSI.
- Patients were good responders in prior ovulation induction cycle.
- There were at least two embryos with grade A in each embryo transfer cycle.
- Normal uterus in Hysterosalpingography (HSG) or ultrasound or hysteroscopy scans.
- The minimum thickness of the endometrium is 7 mm in injection day.
Exclusion Criteria:
- Submucosal myoma.
- Intramural and sub serousal myoma greater than 5 cm.
- Endometrioma equal to or greater than 3 cm or Hydrosalpinx.
- The number of available embryos is less than 2 in the current cycle.
- Patients with endometrial tuberculosis and persons who are treated for tuberculosis.
- Patients with any specific drug consumption.
- Patients with a history of thyroid disease, diabetes and other endocrine disorders.
- Lost to follow up or sampling.
- Impossibility of prepare endometrial sampling because of severe pain or probability infection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Endometrial injury
In the intervention group, endometrial sampling is obtained twice by Pipelle [one in the follicular phase (during 8-9 or 11- 13 day in the beginning of buserelin cycle) and the last in the luteal phase (during 19-21 or 20-23 day) preceding the embryo transfer cycle preceding the embryo transfer cycle].
Blood samples (5- 10 cc) are taken in the both groups twice (one on the 9-8 or 11- 13 day and 19-21 or 20-23 day preceding the embryo transfer cycle).
|
The endometrial injury which is induced with pipelle.
|
|
No Intervention: Control
In the control group endometrial sampling will be done only in the luteal phase of the cycle preceding the embryo transfer cycle.
Blood samples (5- 10 cc) are taken twice (one on the 9-8 or 11- 13 day and 19-21 or 20-23 day preceding the embryo transfer cycle).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
cytokine
Time Frame: 1month
|
Measurement of cytokines in endometrial sample in both group.
|
1month
|
|
growth factor
Time Frame: 1month
|
Measurement of growth factors in endometrial sample in both groups.
|
1month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Expression of TLRs
Time Frame: 1month
|
Evaluation of TLRs expression in endometrial sample in both groups.
|
1month
|
|
Expression of HOX
Time Frame: 1month
|
Evaluation of HOX expression in endometrial sample in both groups.
|
1month
|
|
pregnancy rate
Time Frame: 6months
|
Evaluation of pregnancy rate in both groups.
|
6months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Reza Aflatoonian, PhD, Department of Endocrinology and Female Infertility at Reproductive Biomedicine Research Centre, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.
- Study Director: Mahnaz Ashrafi, MD, Department of Endocrinology and Female Infertility at Reproductive Biomedicine Research Centre, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.
- Principal Investigator: Samaneh Aghajanpour, M.S.c, Department of Endocrinology and Female Infertility at Reproductive Biomedicine Research Centre, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.
- Principal Investigator: Elham Amirchaghmaghi, MD,PhD, Department of Endocrinology and Female Infertility at Reproductive Biomedicine Research Centre, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- royan-Emb-021
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.